Natixis Advisors L.P. Acquires 9,190 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Natixis Advisors L.P. grew its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 11.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,293 shares of the company’s stock after purchasing an additional 9,190 shares during the period. Natixis Advisors L.P.’s holdings in Henry Schein were worth $6,608,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Services Advisors Inc. increased its stake in Henry Schein by 15.8% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 7,057 shares of the company’s stock worth $524,000 after buying an additional 965 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Henry Schein by 8.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,528 shares of the company’s stock valued at $1,747,000 after purchasing an additional 1,773 shares during the period. Mackenzie Financial Corp grew its stake in Henry Schein by 0.9% in the third quarter. Mackenzie Financial Corp now owns 62,672 shares of the company’s stock worth $4,577,000 after purchasing an additional 562 shares in the last quarter. Strs Ohio increased its holdings in Henry Schein by 13.6% during the 3rd quarter. Strs Ohio now owns 30,886 shares of the company’s stock worth $2,293,000 after purchasing an additional 3,687 shares during the period. Finally, IFM Investors Pty Ltd raised its position in Henry Schein by 11.8% during the 3rd quarter. IFM Investors Pty Ltd now owns 27,540 shares of the company’s stock valued at $2,045,000 after purchasing an additional 2,914 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

HSIC has been the topic of a number of recent research reports. Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a research report on Monday, February 26th. JPMorgan Chase & Co. raised their target price on shares of Henry Schein from $82.00 to $88.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. SVB Leerink initiated coverage on shares of Henry Schein in a research report on Monday, February 26th. They issued a “market perform” rating and a $78.00 price target for the company. Piper Sandler lifted their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Monday, February 26th. Finally, UBS Group lowered their target price on Henry Schein from $82.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $81.73.

Insider Activity at Henry Schein

In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Bradford C. Connett sold 6,430 shares of Henry Schein stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Henry Schein Stock Performance

Shares of HSIC stock opened at $73.44 on Friday. Henry Schein, Inc. has a 12-month low of $60.01 and a 12-month high of $82.63. The business’s fifty day simple moving average is $72.95 and its 200-day simple moving average is $72.35. The company has a current ratio of 1.67, a quick ratio of 1.00 and a debt-to-equity ratio of 0.45. The company has a market cap of $9.44 billion, a PE ratio of 23.31, a PEG ratio of 1.68 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.09. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $1.21 EPS. Analysts expect that Henry Schein, Inc. will post 5.07 earnings per share for the current fiscal year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.